Zymeworks Secures $250M Royalty Note, Eyes $440M GEA Milestone Payments
Zymeworks secured Canadian and UK approvals for zanidatamab monotherapy, unlocking up to $440 million in GEA milestone payments plus $89 million from Jazz and BeiGene for a third indication. It raised $250 million via a non-recourse royalty note, posted $106 million in 2025 revenue, trimming net loss to $81.1 million.
1. Regulatory Approvals and Milestone Potential
Zymeworks reported regulatory approvals in Canada and the United Kingdom for zanidatamab monotherapy in second-line biliary tract cancer. The company projects up to $440 million in milestone payments upon global GEA approvals and an additional $89 million from Jazz and BeiGene for a third indication beyond biliary tract cancer and GEA.
2. Royalty-Backed Financing
The company secured $250 million of non-recourse capital through a royalty-backed note with Royalty Pharma, using only 30% of Ziihera royalties for repayment while retaining 70% during the term. This transaction carries no stated interest rate, does not dilute equity, and preserves all future milestone payments for Zymeworks.
3. Q4 Financial Results and Cash Runway
Total 2025 revenue reached $106 million, up from $76.3 million in 2024, driven by collaboration milestones and option exercises, while operating expenses fell to $198.5 million. Net loss narrowed to $81.1 million and cash resources stood at $270.6 million, with runway extending beyond 2028 when including anticipated $440 million in GEA milestones.
4. Clinical Progress and Upcoming Submissions
Zymeworks expects to submit a supplemental BLA for zanidatamab under the FDA Real-Time Oncology Review in Q1 2026, targeting U.S. GEA approval in H2 2026. An additional interim analysis of median overall survival for the zanidatamab-chemotherapy regimen is due by mid-2026, following initial results just missing statistical significance.